Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144105
Status:
TERMINATED
Last Update Posted:
2013-11-01
First Post:
2005-09-02
Brief Title:
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir TPV Plus 100 mg or 200 mg Ritonavir RTV po BID in Comparison to 400 mg Lopinavir LPV Plus 100 mg RTV po BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Organization Data
Organization:
Boehringer Ingelheim
Class:
INDUSTRY
Study ID:
118233
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Boehringer Ingelheim
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None